N6-isopentenyladenosine
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Others |
| Catalog number | BBF-04042 |
| CAS | 7724-76-7 |
| Molecular Weight | 335.36 |
| Molecular Formula | C15H21N5O4 |
| Purity | ≥98% |
Ordering Information
| Catalog Number | Size | Price | Stock | Quantity |
|---|---|---|---|---|
| BBF-04042 | 5 g | $629 | In stock |
Online Inquiry
Add to cartDescription
It is a cytokinin growth regulator that can be produced endogenously by plants to guide the differentiation of callus cells. In the research of anticancer drugs, it can induce cell cycle contraction and apoptosis.
Specification
| Synonyms | N6-(2-Isopentenyl)adenosine; Isopentenyladenosine riboside; N-(3-Methyl-2-butenyl)-adenosine; 6-(3-Methyl-2-butenylamino)-9-β-D-ribofuranosylpurine; 6-(3-Methyl-2-butenylamino)purine riboside; 6-(γ,γ-Dimethylallylamino)purine riboside; N-Isopentenyladenosine; N6-(3-Methyl-2-butenyl)adenosine; NSC 105546; Riboprine; Isopentenyladenosine |
| Storage | Store at 2-8°C |
| IUPAC Name | (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(3-methylbut-2-enylamino)purin-9-yl]oxolane-3,4-diol |
| Canonical SMILES | CC(=CCNC1=C2C(=NC=N1)N(C=N2)C3C(C(C(O3)CO)O)O)C |
| InChI | InChI=1S/C15H21N5O4/c1-8(2)3-4-16-13-10-14(18-6-17-13)20(7-19-10)15-12(23)11(22)9(5-21)24-15/h3,6-7,9,11-12,15,21-23H,4-5H2,1-2H3,(H,16,17,18)/t9-,11-,12-,15-/m1/s1 |
| InChI Key | USVMJSALORZVDV-SDBHATRESA-N |
| Source | Synthetic |
Properties
| Appearance | White to Light Beige Solid |
| Application | Plant Growth Regulators |
| Antibiotic Activity Spectrum | neoplastics (Tumor) |
| Boiling Point | 647.2±65.0°C at 760 mmHg |
| Melting Point | >138°C (dec.) |
| Density | 1.6±0.1 g/cm3 |
| Solubility | Soluble in DMSO (Slightly), Methanol (Slightly, Heated, Sonicated) |
Reference Reading
1.Toxigenic Corynebacterium ulcerans isolated from a wild bird (ural owl) and its feed (shrew-moles): comparison of molecular types with human isolates.
Katsukawa C1, Umeda K2, Inamori I3, Kosono Y4, Tanigawa T5, Komiya T6, Iwaki M7, Yamamoto A6,8, Nakatsu S9. BMC Res Notes. 2016 Mar 22;9(1):181. doi: 10.1186/s13104-016-1979-5.
BACKGROUND: Corynebacterium ulcerans is a pathogen causing diphtheria-like illness to humans. In contrast to diphtheria by Corynebacterium diphtheriae circulating mostly among humans, C. ulcerans infection is zoonotic. The present study aimed to clarify how a zoonotic pathogen C. ulcerans circulates among wild birds and animals.
2.Subtyping of Salmonella enterica Subspecies I Using Single-Nucleotide Polymorphisms in Adenylate Cyclase (cyaA).
Guard J1, Abdo Z1, Byers SO2, Kriebel P2, Rothrock MJ Jr1. Foodborne Pathog Dis. 2016 Apr 1. [Epub ahead of print]
Methods to rapidly identify serotypes of Salmonella enterica subspecies I are of vital importance for protecting the safety of food. To supplement the serotyping method dkgB-linked intergenic sequence ribotyping (ISR), single-nucleotide polymorphisms were characterized within adenylate cyclase (cyaA). The National Center for Biotechnology Information (NCBI) database had 378 cyaA sequences from S. enterica subspecies I, which included 42 unique DNA sequences and 19 different amino acid sequences. Five representative isolates, namely serotypes Typhimurium, Kentucky, Enteritidis phage type PT4, and two variants of Enteritidis phage type PT13a, were differentiated within a microsphere-based fluidics system in cyaA by allele-specific primer extension. Validation against 25 poultry-related environmental Salmonella isolates representing 11 serotypes yielded a ∼89% success rate at identifying the serotype of the isolate, and a different region could be targeted to achieve 100%.
3.Molecular Characterization of a Prevalent Ribocluster of Methicillin-Sensitive Staphylococcus aureus from Orthopedic Implant Infections. Correspondence with MLST CC30.
Montanaro L1, Ravaioli S1, Ruppitsch W2, Campoccia D3, Pietrocola G4, Visai L5, Speziale P4, Allerberger F2, Arciola CR1. Front Cell Infect Microbiol. 2016 Feb 16;6:8. doi: 10.3389/fcimb.2016.00008. eCollection 2016.
Staphylococcus aureus is the leading etiologic agent of orthopedic implant infections. Here a ribocluster of 27 S. aureus strains underwent further molecular characterization and subtyping by multilocus sequence typing (MLST) and spa-typing. This cluster had been detected by automated ribotyping (with the EcoRI restriction enzyme) of 200 S. aureus isolates from periprosthetic infections of patients who underwent revision at the Rizzoli Orthopaedic Institute. The ribocluster, consisting of agr type III strains, with a 74% co-occurrence of bone sialoprotein-binding (bbp) and collagen-binding (cna) genes, lacked mecA and IS256, and exhibited a high prevalence of the toxic shock syndrome toxin gene (tst, 85%). Strains' relatedness was analyzed by BURP and eBURST. Two predominant spa types, t012 (32%) and t021 (36%), and one predominant sequence type, ST30 (18/27, 67%) were identified: a S. aureus lineage spread worldwide belonging to MLST CC30.
4.Laboratory-based surveillance of Clostridium difficile circulating in Australia, September - November 2010.
Cheng AC1, Collins DA2, Elliott B2, Ferguson JK3, Paterson DL4, Thean S5, Riley TV6. Pathology. 2016 Apr;48(3):257-60. doi: 10.1016/j.pathol.2016.02.005. Epub 2016 Mar 2.
Clostridium difficile rose in prominence in the early 2000s with large-scale outbreaks of a particular binary toxin-positive strain, ribotype 027, in North America and Europe. In Australia outbreaks of the same scale had not and have not been seen. A survey of C. difficile across Australia was performed for 1 month in 2010. A collection of 330 C. difficile isolates from all States and Territories except Victoria and the Northern Territory was amassed. PCR ribotyping revealed a diverse array of strains. Ribotypes 014/020 (30.0%) and 002 (11.8%) were most common, followed by 054 (4.2%), 056 (3.9%), 070 (3.6%) and 005 (3.3%). The collection also contained few binary toxin positive strains, namely 027 (0.9%), 078 (0.3%), 244 (0.3%), 251 (0.3%) and 127 (0.3%). The survey highlights the need for vigilance for emerging strains in Australia, and gives an overview of the molecular epidemiology of C. difficile in Australia prior to an increase in incidence noted from mid-2011.
Recommended Products
| BBF-02614 | Nystatin | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
